EverImmune – Villejuif, France
EverImmune has identified Oncobax® AK, Akkermansia, as a key bacterial commensal driving the clinical efficacy of anticancer therapeutics in cancer patients. Oncobax® AK is a single strain bacterium lyophilized and encapsulated that will reach the gates of clinical development early 2022.
romain.daillere@everimmune.com
